News

Biologics in Pregnancy Up Malformation Risk


 

Q: If I take a biologic, will it be more difficult to become pregnant?

A: Information is very limited, but to date neither preclinical data nor clinical data indicate that becoming pregnant is more difficult.

Q. If I do become pregnant while on a biologic drug, do I have a chance of having a baby with a birth defect?

A. One of the principles of teratology is that known teratogens tend to cause specific patterns of malformations. To date with the limited information available, neither animal nor human data suggest that the risk for a specific pattern of defects is increased over baseline if you take a biologic agent while pregnant. While preliminary results from the OTIS project have noted that more malformations occurred in the offspring of women taking etanercept, the defects were varied and isolated.

Q. If I do become pregnant while taking this drug, will my child's immune system be compromised?

A. There are limited human data available for rituximab. To date, the results of the OTIS study do not indicate an increase in opportunistic infections, hospitalizations, or malignancies in the infants of women who have taken etanercept or adalimumab.

Q. If I do become pregnant while taking a biologic agent, do I have to discontinue the drug or can I safely continue to take the drug throughout pregnancy?

A. We really don't know the answer. In the OTIS project, approximately half of women on etanercept or adalimumab remain on the medication into the second or third trimester.

Disclosures: Dr. Chambers has received research grants from Sandoz, Kali Labs, Apotex, Barr Labs, Teva Pharmaceuticals, Amgen, Bristol Myers Squibb, Abbott Laboratories, Sanofi-Aventis Pharmaceutical, and Sanofi-Pasteur.

BY CHRISTINA CHAMBERS, Ph.D.

Pages

Recommended Reading

TNF Blocker Risk-Benefit Analysis Proves Favorable
MDedge Dermatology
Ustekinumab Approved With Safety Requirement
MDedge Dermatology
Antiangiogenesis Offers New Tactic for Inflammatory Disease
MDedge Dermatology
Ustekinumab Found to Help Improve Sexual Function in Psoriasis Patients
MDedge Dermatology
IL-17A Blocker Shows Early Promise for Psoriasis
MDedge Dermatology
IVIG Guidelines Highlight Autoimmune Uses
MDedge Dermatology
UV Exposure May Be Tied to Dermatomyositis in Women
MDedge Dermatology
Drop Methotrexate At Week 12 in Poor Responders : Less than PASI-50 flags need for a biologic.
MDedge Dermatology
Belimumab Shows Efficacy in Second Lupus Trial
MDedge Dermatology
Anti-TNF Agents May Up Skin Cancer Risk
MDedge Dermatology